Given Imaging (Nasdaq: GIVN) reported earnings on Nov. 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Given Imaging missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded slightly and GAAP earnings per share grew significantly.

Margins grew across the board.

Revenue details
Given Imaging logged revenue of $45.4 million. The two analysts polled by S&P Capital IQ expected to see sales of $47.4 million on the same basis. GAAP reported sales were 1.5% higher than the prior-year quarter's $44.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.25. The two earnings estimates compiled by S&P Capital IQ predicted $0.22 per share. GAAP EPS of $0.19 for Q3 were 58% higher than the prior-year quarter's $0.12 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 77.5%, 40 basis points better than the prior-year quarter. Operating margin was 14.2%, 500 basis points better than the prior-year quarter. Net margin was 13.2%, 480 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $52.7 million. On the bottom line, the average EPS estimate is $0.26.

Next year's average estimate for revenue is $187.3 million. The average EPS estimate is $0.62.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 123 members out of 138 rating the stock outperform, and 15 members rating it underperform. Among 23 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give Given Imaging a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Given Imaging is outperform, with an average price target of $19.67.